Craig Venter's in the news. Again.

A research team may have found a way to bring back an anti-cancer drug that never saw the light of day due to toxicity problems.

A Valleywag blogger says George Church and his PGP are a little too closely connected to Google and 23andMe.

Companies aim to help scientists share their work.

Nature reports on structural variation in schizophrenia, miRNAs and protein expression, iPS cells, and more.

NEWSBRIEF

US Patent 7,405,401. Ion extraction devices, mass spectrometer devices, and methods of selectively extracting ions and performing mass spectrometry. Inventor: John Hoyes.

Silence Therapeutics Issued Notice of Allowance for Core US IP   Silence Therapeutics announced this week that the US Patent and Trademark Office has allowed

Agilent Technologies recently introduced a new labeling and hybridization kit for microRNA profiling experiments conducted on the company’s oligo microarrays.  

Isis Pharmaceuticals Executive Vice President Jeffrey Jonas has resigned, the company disclosed last week in a filing with the US Securities and Exchange Commission.  

NEWSBRIEF

NEWSBRIEF

Spike in Bruker Q2 Revs   Bruker announced this week a 30.6 percent increase in revenues for its second quarter ended June 30.   For the quarter, the company posted receipts of $311.5 million, compared to

Ludesi this week introduced Ludesi Basic, a cheaper, “lightweight” version of the company’s premier 2D Gel Image Analysis Service.   Priced at $50, Ludesi Basic is designed for researchers who need &l

In addition to denying charges of scientific misconduct and fraud, Nucleonics’ co-founders also downplayed the role the company’s president and CEO played in establishing the firm’s direction and closing its biggest fund-raising round.

Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules   Number: 7,404,969

NEWSBRIEF

NEWSBRIEF

NEWSBRIEF

A year after saying Caprion Proteomics’ purchase by a hedge fund was positioning it for a bigger payout, the company’s chief executive this week said that the firm’s plan to be bought by a drug maker remains on course, but because of strength in its biomarker-discovery and -validation service business the firm will take its time finding a suitor.

NEWSBRIEF

NEWSBRIEF

NEWSBRIEF

The good news for ABI’s fiscal fourth quarter: The firm halted the slide in its mass spectrometry sales. The bad news: proteomics was excluded from the reversal of fortune.

The tool is a variant of SILAC designed to measure changes in protein synthesis rather than in protein concentrations. When used in combination with microarray analysis of mRNAs, the approach enabled the researchers to pinpoint the effects of microRNAs on translation.